Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New filler aims to restore youthful cheek volume

NCT ID NCT05818709

Symptom relief Sponsor: AbbVie Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a new dermal filler called HAC 22L for improving midface volume loss in adults. About 61 participants received either the filler or delayed treatment. The goal was to see if the filler safely improves cheek fullness. Results are based on doctor ratings and patient satisfaction.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
HAC 22L (hyaluronic acid dermal filler)
What this could lead to
If it works, this could offer a safe and effective option for restoring midface volume lost with aging.
What could go wrong
This is a small, completed Phase 3 trial with only 61 participants. Results may not apply to everyone, and side effects like swelling or bruising are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

61 people

The number who actually took part.

Started

Jun 2023

Finished

Dec 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Participant in general good health * Seeking improvement/correction of mid-face volume * Participant has overall mid-face severity of Moderate (3), Significant (4), or Severe (5) on the 6-point photonumeric MFVDS as assessed by the EI * Participant capable of giving signed informed consent Exclusion Criteria: * Has experienced trauma to the mid-face within 6 months before enrollment or has residual deficiencies, deformities, or scarring. * Conditions that could interfere with device effectiveness such as current cutaneous or mucosal inflammatory or infectious processes (eg, herpes), rosacea, abscess, an unhealed wound, active acne, or a cancerous or precancerous lesion in the mid-face * History of keloid scar formation, hypertrophic scarring, and/or post inflammatory hyperpigmentation * History of pigmentation disorders or current pigmentation disorder in the face * A history of facial surgeries in the mid-face * Received fat injection or permanent implants (eg, polymethylmethacrylate, silicone, polytetrafluoroethylene) anywhere in the face, or is planning to be implanted with any of these products at any time during the study * Received semipermanent soft-tissue filler treatment (eg, calcium hydroxyapatite, poly-L-lactic acid) in the mid-face within 36 months before enrollment, or is planning to be implanted with any of these products at any time during the study * Temporary soft tissue filler injections in the mid-face within 24 months before enrollment * Received botulinum toxin treatment to the midface within 6 months before enrollment, or is planning to undergo any such treatment during the study * Received mesotherapy or cosmetic facial procedures in the mid-face within 6 months before enrollment, or is planning to undergo any such treatment during the study * Any over-the-counter or prescription oral or topical, anti-wrinkle products for the mid-face within 30 days before enrollment (participants who have been on a regimen of such products for at least 30 days are eligible for the study if they intend to continue their regimen throughout the study) * Is on a prescribed regimen of anti-coagulation therapy (eg, warfarin, clopidogrel) * Tattoos, piercings, hair, or scars that would interfere with visualization of the cheek area for the effectiveness assessments * Pregnant, nursing, or planning a pregnancy

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Facial volume deficit are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Facial volume deficit

Contacts and locations

Locations

  • Antiaging Group Barcelona (AGB) /ID# 245446

    Barcelona, 08021, Spain

  • Dermatologie Mahlow /ID# 243805

    Blankenfelde-Mahlow, Brandenburg, 15831, Germany

  • Grupo Pedro Jaen /ID# 243347

    Madrid, 28006, Spain

  • Haut- und Lasercentrum Potsdam /ID# 243822

    Potsdam, Brandenburg, 14467, Germany

  • Hautarztpraxis Dr. Niesmann und Dr. Othlinghaus /ID# 243802

    Bochum, North Rhine-Westphalia, 44793, Germany

  • Hautok and Hautok-cosmetics /ID# 243800

    Munich, Bavaria, 80333, Germany

  • Hautzentrum Koeln /ID# 244607

    Cologne, North Rhine-Westphalia, 50996, Germany

  • Instituto Medico Miramar /ID# 251640

    Málaga, Malaga, 29016, Spain

  • Instituto de Dermatologia Integral (IDEI) /ID# 245764

    Madrid, 28009, Spain

  • Instituto de Medicina y Dermatologia Avanzada (IMDA) /ID# 243339

    Madrid, 28001, Spain

  • MediCorium Zentrum fuer Dermatologie und Aesthetik /ID# 243799

    Oberursel, Hesse, 61440, Germany

  • Noahklinik GmbH /ID# 244610

    Kassel, 34117, Germany

  • Privatpraxis Dr. Hilton & Partner /ID# 243798

    Düsseldorf, North Rhine-Westphalia, 40212, Germany

  • Privatpraxis fuer Dermatologie und Aesthetik /ID# 243803

    München, 80539, Germany

  • Rosenpark Research /ID# 243804

    Darmstadt, Hesse, 64283, Germany

  • Sclinic /Id# 243340

    Madrid, 28001, Spain

  • Universitaet Hamburg /ID# 251970

    Hamburg, 20146, Germany